The difference between hemoglobin, erythrocytes, leukocytes, and thrombocytes before and after cisplatin chemotherapy in stage III B cervical cancer patients at Oncology Clinic of Dr. Soetomo General Hospital

This study aimed to evaluate the differences in hemoglobin, erythrocyte, leukocyte, and thrombocyte levels before and after neoadjuvant cisplatin chemotherapy and radiotherapy in stage IIIB cervical cancer patients at Oncology Clinic of Dr. Soetomo General Hospital, Surabaya. The data were obtained from secondary sources and analyzed using a paired t-test. The majority patients were aged 40-59 years and originated from outside Surabaya. The most common parity was three, and abnormal vaginal bleeding was the most frequently reported symptom. The mean hemoglobin level decreased from 10.94 ± 2.21 g/dL to 10.61 ± 1.66 g/dL (p = 0.281), but the change was not clinically significant. Similarly, the mean erythrocyte levels decreased from 4.09 ± 0.06 x 106/ µL to 3.36 ± 0.58 x 106/µL (p = 0.001), with no significant effect observed. The mean leukocyte levels showed a significant decrease from 11.17 ± 4.73 x 103/dL to 9.62 ± 4.56 x 103/µL (p = 0.029), indicating leukopenia as a notable side effect of chemoradiation. The mean thrombocyte levels also decreased from 385.98 ± 133.85 x 103/µL to 342.08 ± 118.24 x 103/µL (p = 0.023), without significant difference. The findings suggest that cisplatin-based chemoradiotherapy has a significant impact on leukocyte levels, whereas changes in hemoglobin, erythrocytes, and thrombocytes were not statistically significant. These results are consistent with previous studies that emphasize leukopenia as a major hematological toxicity from chemoradiation. Monitoring blood cell parameters is essential in the management of cervical cancer patients undergoing this therapy.